To investigate if the tumor suppressor properties of p57KIP2 are dependent on its DNA methylation status, we studied the impact of several stress stimuli in leukemic cell lines with different p57KIP2 promoter DNA methylation levels. p57KIP2 reactivation was observed after stimulation with transforming growth factor-b, other cytokines, high-density culture or serum withdrawal in p57KIP2 promoter unmethylated cells but not in methylated cells. In these cells, p57KIP2 reactivation required the use of a hypomethylating agent or a histone deacetylase inhibitor. Overexpression of p57KIP2 in p57KIP2 promoter methylated leukemic cell lines resulted in cell growth arrest and the induction of apoptosis. In contrast, overexpression of p57KIP2 in partially methylated cells only resulted in a moderate inhibition of cell growth and had no impact on apoptosis. Transduction of unmethylated cells expressing high levels of p57KIP2 with p57KIP2 short hairpin RNA resulted in increased cell proliferation. These results suggest that the tumor suppressive properties of p57KIP2 in leukemia may depend on the intrinsic promoter DNA methylation status of the gene.
Introduction
Epigenetic repression via aberrant DNA methylation of genes involved in cell-cycle control is a frequent characteristic of human leukemia (Melki et al., 1999; Toyota et al., 2001; Garcia-Manero et al., 2002) . This phenomenon is particularly prevalent in acute lymphocytic leukemia (ALL) where a significant subset of patients, both adult and pediatric, are characterized by the concomitant methylation of multiple promoter-associated cytosine guanine dinucleotide islands (Garcia-Manero et al., 2002 Gutierrez et al., 2003; Roman-Gomez et al., 2004) . This hypermethylator phenotype is associated with a poor prognosis (Garcia-Manero et al., 2002; Roman-Gomez et al., 2004) .
Cell cycle progression is regulated by a large number of protein families (Sherr, 2000) . Disruption of this complex machinery may result in altered cell growth, apoptosis and differentiation (Malumbres et al., 2004) . In accordance with these results, we have shown that aberrant DNA methylation of a cellcycle control pathway composed of p73, p15 and p57KIP2 identifies a subset of adult patients with ALL and poor prognosis (Shen et al., 2003) . The prognostic value of this pathway is maintained at the protein level. Patients whose leukemic blasts express these proteins, and in particular p57KIP2, have a better prognosis (Bueso-Ramos et al., 2005) . Moreover, methylation of this pathway in pediatric patients with ALL, that in general have a better prognosis than the adult counterparts, is less frequent (Canalli et al., 2005) . These data thus suggest that p57KIP2 plays a key role in ALL. Recently, Scandura et al. (2004) have demonstrated that p57KIP2 is a key mediator of transforming growth factor-b (TGF-b) signaling in hematopoietic cells.
Based on this, we studied the cellular and molecular effects of expression of p57KIP2 in leukemia cell lines with different p57KIP2 promoter methylation levels. We were interested in analysing if the tumor suppressor properties of the gene could be mediated by its intrinsic DNA methylation status, and whether the effects of re-expression of p57KIP2 would be different in cells in which the promoter of the gene is methylated compared to cells in which is not. To perform these experiments, we have tested several cell culture conditions and developed stable leukemia cell p57KIP2 transfectants using a lentivirus system. Our results identify p57KIP2 as a tumor suppressor gene in leukemia but only in cell lines with a methylated p57KIP2 promoter.
Results
Distinct patterns of p57KIP2 expression regulation in p57KIP2 methylated/silenced or unmethylated/unsilenced cell lines p57KIP2 has been previously shown to be aberrantly methylated and silenced in leukemia cell lines. In this study, these initial observations were confirmed using the combined bisulfite restriction assay (COBRA) (Xiong and Laird, 1997; Shen et al., 2003) , real-time polymerase chain reaction (PCR) and Western blot in 17 leukemia cell lines (Supplementary Figure 1 and Table 1 ). These data indicate that as previously reported (Kikuchi et al., 2002) there is a strong association, although not universal, between aberrant DNA methylation of the p57KIP2 promoter and its silencing.
To study the patterns of p57KIP2 mRNA expression in leukemia cells, we examined its expression in response to a variety of growth arrest stimuli in K562, Jurkat and Raji cells, which represent p57KIP2 unmethylated/ unsilenced, partially methylated/unsilenced and densely methylated/silenced cell lines, respectively (Supplementary Figure 1 and Table 1 ). As shown in the real-time PCR analysis in Figure 1a , in Jurkat cells p57KIP2 mRNA expression was upregulated 24 h after treatment with TGF-b, lipopolysaccharide (LPS), tumor necrosis factor-a (TNF-a) and insulin-like growth factor 1 (IGF1) but not with dexamethasone, suberoylanilide hydroxamic acid (SAHA) or 5-aza-2 0 -deoxycitidine. The same results were observed in K562 cells (data not shown). In an additional experiment (Figure 1c ), Jurkat cells were treated for 0-72 h with TGF-b. Upregulation of p57KIP2 mRNA was observed after 3 h and peaked at 24 h. TGF-b treatment had no effect on the expression of other cyclin-dependent kinase inhibitors (CDKIs) such as p21, p27, and p15 or p73, cyclin E and cdk2 in Jurkat cells either by real-time PCR or Western blot (data not shown). Of interest, the induction of p57KIP2 by TGF-b was insufficient to arrest cell proliferation or cell cycle, or to induce apoptosis, in these cells (data not shown).
In contrast, TGF-b, LPS and TNF-a treatment did not result in up-regulation of p57KIP2 in Raji, PEER and Ramos cell lines (Figure 1b and d, data not shown), indicating that the methylated p57KIP2 promoter is not responsive to these growth arrest stimuli. However, exposure to the hypomethylating agent 5-aza-2 0 -deoxycitidine or the histone deacetylase inhibitor SAHA restored expression of p57KIP2 in these cell lines. As shown in Figure 1b , p57KIP2 mRNA expression was induced by 5-aza-2 0 -deoxycitidine alone or by combination with SAHA, but not by SAHA alone, in Raji and PEER cells (data not shown), whereas the reverse was observed in Ramos (data not shown). This indicates that the response of p57KIP2 to TGF-b stimulation is dependent on its epigenetic status. Induction of p57KIP2 results in cell-cycle arrest in response to high-density cell culture and serum deprivation, but this effect is dependent on the DNA methylation status of the p57KIP2 promoter To study the effects of p57KIP2 promoter methylation on cell growth arrest, we analysed the relation between p57KIP2 mRNA expression and cell cycle-progression by artificially inducing cell-cycle arrest by highdensity cell culture or serum deprivation. Jurkat cells expressed p57KIP2 mRNA in a cell density-dependent manner (Figure 2a) . The serum-withdrawal experiment showed results similar to those of the highdensity culture system in Jurkat cells (Figure 2b ), as well as progressive p57KIP2 protein accumulation ( Figure 2d ) and evoked G2 arrest and increased in the subG1 fraction at 24 h followed by a significant increase in the subG1 fraction at 48 h (Figure 2d ). In contrast, high-density cell culture and serum deprivation did not increase p57KIP2 mRNA expression in p57KIP2 methylated/silenced Raji cells (Figure 2c ). In these cells, treatment with the hypomethylating agent 5-aza-2 0 -deoxycytidine alone resulted in a significant decrease in cell viability, and induction of apoptosis (Figure 3a, c and d) , and re-expression of p57KIP2 mRNA and p57KIP2 hypomethylation (Figure 3b ). These findings suggest that p57KIP2 gene expression is closely related to cell-cycle progression in p57KIP2 unmethylated cells, but not in epigenetically repressed cells.
To further investigate the role of p57KIP2 in cell cycle control in leukemia cells, we constructed a phosphory- p57KIP2 tumor suppressor properties in leukemia S-Q Kuang et al that p57KIP2 overexpression resulted in induction of cell-cycle arrest in the G2/M phase in these cells (data not shown).
Exogenous expression of p57KIP2 in methylated Raji cells induced apoptosis and suppressed cell growth
To investigate the function of p57KIP2 in Raji cells, in which the promoter of p57KIP2 is methylated, we used a modified lentivirus gene transfer method to transduct the p57KIP2 complementary DNA (cDNA) construct (Ling et al., 2003; Ling and Arlinghaus, 2005) . The bi-cistronic lentivirus vector contains internal ribosome entry site to allow translation of p57KIP2 and green fluorescent protein (GFP) from one transcript. Expression of GFP, determined by flow cytometry, was used to identify successfully transduced cells. Expression of p57KIP2 mRNA was detected by reverse transcriptase-PCR (RT-PCR) in p57KIP2/GFP lentivirus-infected cells but not in GFP lentivirus-infected cells after 48 h post-infection (Figure 4a ). p57KIP2-lentivirus-infected cells displayed morphological alterations characteristic of apoptotic cell death as early as 24 h after infection. Cells became rounded and shrunken, with blebbing of the cytoplasmic membrane. Microscopic analysis of 4 0 ,6-diamidino-2-phenylindole (DAPI)-stained cells demonstrated that most of p57KIP2-lentivirus-infected cells had enlarged nuclei with condensed and marginalized chromatin after 48 h post-infection (Figure 4b ). In comparison, the empty vector-treated cells had evenly distributed nuclei through the experiment. That p57KIP2 overexpression resulted in the induction of apoptosis in Raji cells was confirmed by annexin V-propidium iodide (PI) staining (Figure 4c and d): 24 h after transduction with p57KIP2-lentivirus, 16.2% of cells were undergoing apoptosis, at 48 h 76.8% and by 72 h 92%. In comparison, only 10% of empty vector-infected cells were apoptotic 48-72 h after infection. The effect of p57KIP2 overexpression on Raji cell growth was examined by counting viable cells, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell proliferation and colony formation assays. At 24 h after infection, successfully transduced cells were purified. Over the next 96 h, cell counting and MTS assays were performed, and expression of the p57KIP2/GFP marker was analysed. These analyses demonstrated that p57KIP2-lentivirus-transduced cells display dramatic cell growth and proliferation inhibition when compared to cells transduced with the empty vector (Figure 4e and f) . In addition, the colony numbers of p57KIP2-lentivirus-transduced cells significantly decreased compared with that of empty vector-transduced cells (Po0.001) (Figure 4g and h). Lentivirus transfection of PEER cells that are densely methylated for p57KIP2 also resulted in significant loss of cell viability (Supplementary Figure 2) . Taken together, these data suggest that epigenetic silencing of p57KIP2 in Raji and PEER cells may be critical for their survival, supporting the notion that p57KIP2 functions as a tumor suppressor in cells where the gene is aberrantly methylated. Exogenous expression of p57KIP2 in Jurkat cells only partially inhibits cell growth and has no effect on apoptosis The consequences of p57KIP2 overexpression in Jurkat cells were also studied by infecting cells with p57KIP2-lentivirus. In contrast to Raji cells, in which induction of apoptosis was observed, transduction of Jurkat cells that are partially methylated but express p57KIP2, did not result in significant cell kill. Successfully transduced Jurkat cells were sorted 72 h after infection. The expression and nuclear localization of exogenous p57KIP2 in Jurkat cells were confirmed using immunofluorescence (Figure 5a ). Western blot analysis demonstrated that the ectopic expression of p57KIP2 in Jurkat cells was significantly stronger than that of endogenous or empty vector-infected Jurkat cells (Figure 5b ). The effect of p57KIP2 on Jurkat cell growth was examined by counting viable cells, MTS cell proliferation and colony formation assays as described above. The growth and proliferation rate in p57KIP2-lentivirus-transduced Jurkat cells was faster than p57KIP2-lentivirus-transduced Raji cells; but significantly decreased compared with Jurkat cells transduced with empty lentivirus (Figure 5c p57KIP2 tumor suppressor properties in leukemia S-Q Kuang et al Figure 5e ), but significantly higher than Raji transduced cells. This analysis suggests that p57KIP2 only partially inhibited Jurkat cell growth and proliferation.
To investigate whether p57KIP2 sensitizes Jurkat cells to apoptotic stimuli, we treated cells with staurosporine, and subsequently analysed morphological changes and annexin V-PI staining. In contrast to Raji cells, overexpression of p57KIP2 by itself had only minor effect in inducing apoptosis in Jurkat cells (from 10 to 15%). This was minimally enhanced by exposing cells to staurosporine (Figure 5f ). These results indicate that the overexpression of p57KIP2 only results in partial abrogation of cell growth and has minimal apoptotic effect in Jurkat cells. It should be noted that only GFPpositive Raji and Jurkat cells were used for these experiments, and that the levels of protein overexpression were similar by Western blot analysis in both cells lines (data not shown), thus excluding the possibility that the differential effects observed are due to differences in p57KIP2 dosage. Effect of p57KIP2 inhibition mRNA expression by short hairpin RNA in K562 cells To further elucidate the role of p57KIP2 in leukemia cells, we generated two p57KIP2 short hairpin RNAs (shRNAs)-lentivirus constructs to specifically knockdown p57KIP2 expression in K562 cells, in which the promoter of p57KIP2 is unmethylated and fully expressed (Figure 6a and b) . K562 cells transduced with either of the constructs showed an increased growth rate compared to each parental cell line transfected with an empty vector (Figure 6c ). Therefore, a basal level of p57KIP2 expression is required for p57KIP2 CDKI function in restraining the proliferation of K562 cells.
Discussion p57KIP2 (CDKN1C) is a CDKI with an important role in cell-cycle transition control independent of p53 activity (Matsuoka et al., 1995) . It is located in 11p15.5, a region frequently involved in cancer, including patients with the Beckwith-Wiedemann syndrome, and is considered a tumor suppressor gene (Yan et al., 1997; Takahashi and Nakayama, 2000) . Despite this, p57KIP2 mutations have not been frequently observed in sporadic cancers (Kondo et al., 1996; Orlow et al., 1996; Tokino et al., 1996; Bonilla et al., 1998) , except in patients with familial Beckwith-Wiedemann syndrome (Hatada et al., 1996; Lam et al., 1999) . In contrast with the lack of mutations, downregulation of p57KIP2 has been reported in a number of human malignancies including leukemia (Kondo et al., 1996; Kikuchi et al., 2002; Sui et al., 2002; Li et al., 2003; Bueso-Ramos et al., 2005) . This is of importance, as p57KIP2 is an incompletely imprinted gene with significant paternal allele expression Taniguchi et al., 1997) . Following this observation, aberrant DNA methylation of a critical region in the close proximity of the p57KIP2 promoter has been associated with gene inactivation, a phenomenon reversed by exposing methylated cell lines to a hypomethylating agent (Kikuchi et al., 2002) . Furthermore, aberrant DNA methylation of p57KIP2 has been observed in patients with lymphoma and ALL (Shen et al., 2003) , and its inactivation is associated with a worse prognosis in this last subgroup of patients (Shen et al., 2003; BuesoRamos et al., 2005) . Based on this information, we decided to study the cellular and molecular implications of p57KIP2 expression and inhibition in a number of leukemia cell lines. These different cell lines were selected based on the methylation/expression status of the gene, with cell lines being methylated and silenced (Raji) and others being unmethylated and able to express the gene (Jurkat, K562). To initiate these studies, first we confirmed that aberrant DNA methylation of p57KIP2 is a frequent event in a large number of leukemia cell lines, and that, in general, methylation of the area described by Kikuchi et al. (2002) in the proximity of the promoter is associated with gene silencing. It should be noted that as expected the relationship between DNA methylation and p57KIP2 expression is not universal (Supplementary Table 1 ), indicating that other mechanisms of p57KIP2 expression regulation exist.
TGF-b is a negative regulator of hematopoiesis maintaining hematopoietic stem cells in a quiescent undifferentiated state (Ohta et al., 1987) . Scandura et al. (2004) have previously demonstrated that the negative regulatory effect of TGF-b in hematopoietic cells is exclusively mediated by induction of p57KIP2. Therefore, deregulation of TGF-b signaling will have a significant effect in the control of hematopoietic proliferation. Our studies support the results of Scandura et al. (2004) , but add to their observation in that the control of p57KIP2 by TGF-b is mediated by the methylation status of the p57KIP2 promoter. p57KIP2 promoter-methylated cells only responded to epigenetic modulation, such as the use of hypomethylating agent or a histone deacetylase inhibitor, but not to TGF-b. In contrast, unmethylated cells responded to TGF-b stimulation. Moreover, stimulation of p57KIP2 mRNA expression using different forms of cellular stress, such as serum deprivation or high-density cell culture, resulted in different effects in p57KIP2 promoter-methylated versus -unmethylated cells. In unmethylated cells, p57KIP2 was reactivated by these stress stimuli, and this was associated with G2 arrest and induction of apoptosis. This was not observed in methylated cells. These data suggest that p57KIP2 promoter-methylated cell lines are insensitive to the control of TGF-b, and have important implications for p57KIP2 tumor suppressor properties in leukemia S-Q Kuang et al the understanding of epigenetic regulation of TGF-b signaling in hematopoietic cells. It should be noted that this phenomenon seems to be restricted to lymphoid leukemia cells, as p57KIP2 promoter methylation is a rare event in acute myelogenous leukemia (G GarciaManero, unpublished data) (Garcia-Manero et al., 2004) .
After observing that the response to TGF-b or different stress stimuli is mediated by the methylation status of the p57KIP2 promoter, we attempted to study the effects of p57KIP2 overexpression using different transfection systems. We could only transiently transfect the non-leukemia cell line 293T. To circumvent this problem, we developed a lentivirus system to stably transfect different leukemic cells. The results of these experiments are of importance as they demonstrated that p57KIP2 can function as a tumor suppressor gene in leukemia, but that this effect is mediated, at least in part, by the intrinsic cellular methylation state of the gene. To our knowledge, this is one of the strongest evidence that p57KIP2 is a tumor suppressor gene in leukemia, and one of the first reports to indicate that the tumor suppressor properties of a gene are related to its cellular methylation state. In p57KIP2 promotermethylated cells, the expression of p57KIP2 resulted in dramatic morphologic changes, induction of apoptosis and severe inhibition of cell growth. In contrast, in unmethylated cells the introduction of p57KIP2 did not result in a significant induction of apoptosis, although a mild decrease in cell proliferation and colony formation was observed. Treatment of p57KIP2 promoterunmethylated transfected cells with staurospine failed to induce apoptosis in those cells. To further study, the role of p57KIP2 in leukemia, we also used the lentivirus system encoding p57KIP2 shRNA to knockdown the mRNA expression of p57KIP2. K562 cells in which p57KIP2 was knocked down had a significant increased in growth rate compared to the parental cells, thus further demonstrating the importance of p57KIP2 function in these cell systems.
These results have important implications. First, they demonstrate that the study of the function of a tumor suppressor gene may be conditioned by the methylation status of its promoter. So the cellular consequences of the reintroduction of a particular gene, as shown here for p57KIP2, are dramatically different in cells where the gene is inactivated by aberrant DNA methylation. This would indicate that cellular behavior, and by extension the clinical course of the primary clinical models (as already shown), is dictated by adaptive processes related to the epigenetic makeup of critical genes for that particular cell/tissue. Second, and based on this, the results presented here have implications for the use of hypomethylating agents in leukemia, as this information may allow the identification of subset of patients with methylation of specific target genes that may be more responsive to the use of epigenetic therapy.
There are several limitations to the present study, these include the relative small number of cells studied and the fact that we have not analysed primary leukemic cells. The analysis of more cell lines with different p57KIP2 methylation backgrounds will be of importance to confirm these results. Despite these limitations, the data presented here have important implications. First, it suggests that the function of a tumor suppressor gene should be considered based on its epigenetic characteristics. Second, it supports the hypothesis that epigenetic therapy will be significantly more active in patients in which a target gene, in this case p57KIP2 in ALL, is epigenetically silenced than in patients in which is not. This information has obvious implications for the development of epigenetic therapy in cancer.
Materials and methods
Cell culture Details of cell culture conditions are shown in Supplementary Information. The following human leukemia and lymphoma cell lines were studied: MOLT4, Jurkat, PEER, T-ALL1, CEM, Raji, REH, Ramos, K562, BV173, HL60, NB4, THP1, U937, ML1, ALL1 and OCI-AML3.
DNA extraction, bisulfite treatment and DNA methylation analysis DNA was extracted from cell lines using standard phenolchloroform methods. Bisulfite treatment of genomic DNA was performed as described (http://www.3.mdanderson.org/ leukemia/methylation). p57KIP2 DNA methylation was analysed using the COBRA assay as described (Xiong and Laird, 1997; Shen et al., 2003) .
Analysis of gene expression
This was performed using both conventional RT-PCR and real-time PCR assays described in Supplementary Information. pEGFP-p57KIP2 chimera construction and transient transfection PBS-p57KIP2 plasmid that contains full-length human p57KIP2 cDNA was provided by Dr Puming Zhang (Baylor College of Medicine, Houston, TX, USA). Details are shown in Supplementary Information.
Lentivirus generation and infection
Details of lentivirus generation and infection are shown on Supplementary Information.
Immunoblot analysis
Western blot analysis was performed as previously described (Kuang et al., 2002; Yang et al., 2005) . Details are shown in Supplementary Information.
Cell growth, proliferation and colony formation in soft agarose Details are shown in Supplementary Information.
Cell cycle analysis
This was performed using standard procedures. This is detailed in Supplementary Information.
Analysis of apoptosis
Immunofluorescence staining This is detailed in Supplementary Information. p57KIP2 tumor suppressor properties in leukemia S-Q Kuang et al
